BTO Pharm. Co., Ltd.   Report issue

For profit Phase 3
Founded: Seoul Korea, Republic of (1985)
Status: Acquired by CrystalGenomics, Inc. (2015)

Organization Overview

First Clinical Trial
2013
NCT01804361
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2013

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 3 Trials (1)

cyclosporine (sandimmune) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Dry Eye Syndromes (Phase 3)

Keratoconjunctivitis Sicca (Phase 3)

Syndrome (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 1